The 65% revenue growth and raised guidance are strong positive signals for a commercial-stage medtech company. However, the widening operating losses and cash burn rate (~$15.8M per quarter from cash/marketable securities decline) mean the company will likely need to raise capital within the next 6-9 months. Monitor the Q2 2026 earnings for continued revenue acceleration and any update on the path to profitability.
Price Chart
Executive Summary
Shoulder Innovations reported Q1 2026 net revenue of $16.7M (+65% YoY), beating the $14.5M consensus, and raised full-year 2026 revenue guidance to $65M-$68M (from $62M-$65M). However, GAAP net loss per share was -$0.41, which is worse than the -$0.38 reported in Q4 2025 and below the Street consensus of -$0.44 for Q1 2026 (though the filing does not provide a consensus comparison for this quarter). The company remains deeply unprofitable with an operating loss of $9.0M and negative adjusted EBITDA of $7.0M, while cash burn continues.
Key Financial Metrics
Key Facts
- Q1 2026 net revenue of $16.7M, +65% YoY vs $10.1M in Q1 2025
- Raised FY2026 revenue guidance to $65M-$68M (prior: $62M-$65M), representing 37%-44% YoY growth
- Gross margin improved to 77.7% from 76.9% in Q1 2025
- Implant systems sold increased 51% YoY to 2,184 units
- Average selling price rose 9% to $7,650 per system
- GAAP net loss per share was -$0.41 vs -$52.13 in Q1 2025 (prior year had far fewer shares outstanding)
- Operating loss widened to $9.0M from $4.3M in Q1 2025 due to increased SG&A and R&D spending
- Cash and marketable securities totaled $108.5M as of March 31, 2026, down from $124.3M at year-end 2025
- Full commercial launch of InSet I-135RFX Humeral Stem initiated
Financial Impact
Revenue beat consensus by ~15% ($16.7M vs $14.5M est). Guidance raised by $3M at midpoint ($66.5M vs $63.5M prior).
Risk Factors
- Cash burn rate of ~$15.8M per quarter implies ~7 quarters of runway at current cash levels
- Operating losses continue to widen as SG&A and R&D expenses grow faster than revenue
- No EPS consensus beat for this quarter — GAAP EPS of -$0.41 is worse than the -$0.38 reported in Q4 2025
- High dependence on continued adoption by surgeons and hospitals in a competitive market
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001699350-26-000033 |
| Document: si-20260513.htm | 0001699350-26-000033 |
| Document: 0001699350-26-000033-index-headers.html | 0001699350-26-000033 |
| Document: 0001699350-26-000033-index.html | 0001699350-26-000033 |
| Document: 0001699350-26-000033.txt | 0001699350-26-000033 |
| 8-K Data (Synthetic) | 0001699350-26-000033 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 15, 2026 11d ago | Press Release | $18.09 | awaiting T+60 | — | $19.66 (+8.68%) |
Oct 8, 2026 18d ago | 8-K | $17.89 | awaiting T+60 | — | $19.66 (+9.89%) |
Aug 24, 2026 9w ago | Insider Cluster | $22.32 | awaiting T+60 | — | $19.66 (−11.92%) |
Aug 14, 2026 10w ago | EFFECT | $20.73 | awaiting T+60 | — | $19.66 (−5.16%) |
Aug 10, 2026 11w ago | 8-K | $20.75 | awaiting T+60 | — | $19.66 (−5.25%) |
Jul 29, 2026 12w ago | 144 | $23.72 $19.75 | ▲ +16.74% | ▲ +21.47% | $19.66 (+17.12%) |
Jun 29, 2026 17w ago | 8-K | $21.09 $17.61 | ▼ −16.50% | ▼ −20.89% | $19.66 (−6.78%) |
May 13, 2026 23w ago | 8-K | $15.59 $20.75 | ▲ +33.10% | ▲ +29.51% | $19.66 (+26.11%) |
Apr 29, 2026 25w ago | DEFA14A | $12.28 $20.41 | ▲ +66.21% | ▲ +62.09% | $19.66 (+60.10%) |
Apr 27, 2026 26w ago | 8-K | $13.53 $20.31 | ▲ +50.11% | ▲ +45.33% | $19.66 (+45.31%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers